Summary. The tissue factor (TF) pathway plays a central role in hemostasis and thrombo-inflammatory diseases. Although structure-function relationships of the TF initiation complex are elucidated, new facets of the dynamic regulation of TF's activities in cells continue to emerge. Cellular pathways that render TF non-coagulant participate in signaling of distinct TF complexes with associated proteases through the protease-activated receptor (PAR) family of G protein-coupled receptors. Additional coreceptors, including the endothelial protein C receptor (EPCR) and integrins, confer signaling specificity by directing subcellular localization and trafficking. We here review how TF is switched between its role in coagulation and cell signaling through thiol-disulfide exchange reactions in the context of physiologically relevant lipid microdomains. Inflammatory mediators, including reactive oxygen species, activators of the inflammasome, and the complement cascade play pivotal roles in TF procoagulant activation on monocytes, macrophages and endothelial cells. We furthermore discuss how TF, intracellular ligands, co-receptors and associated proteases are integrated in PAR-dependent cell signaling pathways controlling innate immunity, cancer and metabolic inflammation. Knowledge of the precise interactions of TF in coagulation and cell signaling is important for understanding effects of new anticoagulants beyond thrombosis and identification of new applications of these drugs for potential additional therapeutic benefits.
Introduction
The isolation of tissue factor (TF) protein and the subsequent cloning of the coding sequence by several independent laboratories in 1987 revealed the evolutionary origin of TF as a member of the cytokine receptor family and set the stage for a rapid elucidation of the structure-function relationships of the TF-FVIIa coagulation initiation complex. The interactions of macromolecular substrates factor (F)X and FIX have been mapped to some extent by mutagenesis and modeling [1] and structural information of prototypic inhibitor interactions with the TF-FVIIa complex [2, 3] . Despite this initial progress in understanding the structural basis for the function of TF-initiated coagulation, novel posttranscriptional and post-translational mechanisms have emerged that are crucial determinants for the distinct roles of TF in hemostasis and thrombosis. These pathways are also central for TF regulation, trafficking and localization in cells and therefore influence the pleiotropic functions of TF-associated proteases in cell signaling involving the PAR family.
This review will focus on recent progress in three areas. First, we will discuss the role of TF expressed by vascular and extravascular cells in hemostasis and thrombosis. We will then address how inflammatory mediators and other stress signals feed into pathways that switch TF to a procoagulant form by thiol-disulfide exchange reactions in the context of physiologically relevant lipid microdomains. Lastly, we describe the progress made in our understanding of how TF, intracellular ligands, co-receptors and associated proteases are integrated in PARdependent cell signaling pathways controlling innate immunity, cancer and metabolic inflammation.
Cell type-specific roles of TF in thrombosis and hemostasis
Tissue factor is constitutively expressed in epithelia and perivascular barriers of the brain, skin, lung, intestine and placenta. There is consensus that extravascular TF serves as a protective hemostatic envelope. In contrast, the function and cell-type specific expression of TF by intravascular cells, including leukocyte populations, platelets and the endothelium, in pathophysiological processes remain incompletely understood. In addition, new insights into the biochemistry of TF-initiated coagulation and its regulation provide evidence for distinct pathways by which TF contributes to hemostasis vs. thrombosis.
Tissue factor is traditionally viewed as the trigger that provides limited amounts of thrombin for initiation of coagulation (see thin arrows in Fig. 1A ). Thrombin then activates the plasmatic cofactors V and VIII and enables coagulation amplification by FIXa generated by either TF-FVIIa, the FXII contact pathway or thrombin-activated FXIa (thick arrows in Fig. 1A ). These concepts were developed under static assay conditions in which thrombin rapidly accumulates and readily escapes dilution by blood flow and physiological neutralization by fibrinogen and the vessel wall. This led to an underappreciation of roles played by FXa in cofactor activation and its regulation.
Whole human blood and in vivo studies in rabbits with a tick-derived inhibitor specifically blocking FXamediated FV activation revealed a crucial role for FXa in generating an active prothrombinase complex [4] (thin arrows in Fig. 1B ). Several laboratories have also provided evidence that TF pathway inhibitor (TFPI) is the major physiological inhibitor that controls FXamediated activation of FV [5] . Whereas both splice isoforms, TFPIa and TFPIb, inhibit TF-FVIIa, only TFPIa regulates prothrombinase formation by interaction of its positively charged carboxyl-terminus with an acidic FV B-domain exosite exposed by FXa cleavage or by increased alternative splicing in the East Texas bleeding disorder [6] . In addition, FV Leiden is more resistant to control by TFPIa, contributing to the thrombosis risk in carriers of this prothrombotic mutation [7] .
TFPIa inhibits FV activation in simulated reactions of TF-initiated coagulation, but, surprisingly, under the same conditions TFPIa did not interfere with FXa activation of the anti-hemophilic cofactor VIII [8] . The nascent product FXa can be trapped with a nematode inhibitor, NAPc2 [9] ; in this complex FXa still activates FVIII, but not FV. Mutants of FVIIa capable of activating FX, but defective in releasing the newly formed product FXa, show that the TF-FVIIa-FXa coagulation initiation complex directly activates both, cofactor VIII and enzyme FIX, leading to thrombin generation in flowing blood (thick arrows in Fig. 1B ). Unlike the formation of an active prothrombinase, this pathway is poorly inhibited by TFPIa and sufficient for fibrin formation in reconstituted whole blood under flow ex vivo. These experiments suggest that the hemostatic function of TF is triggered early and prior to amplified thrombin generation that requires undocking of FXa for generation of the prothrombinase. Imbalances in plasma exposure to active TF and circulating coagulation inhibitors, including TFPIa, thus favor direct prothrombinase generation by the TF pathway and intravascular thrombosis. This new concept of coagulation initiation by TF and the demonstrated distinct roles for TFPI in regulating TF initiation of the hemostatic FVIII pathway and the generation of prothrombotic prothrombinase raises important new questions on how anticoagulant drugs interfere with these distinct biochemical routes of the TF pathway. Whereas epithelial cell-expressed TF has clearly been linked to the prevention of hemorrhage in a murine acute lung injury model [10] and arterial thrombosis following ferric chloride (FeCl 3 ) injury induced in mice involves vessel wall TF expressed by smooth muscle cells [11] , the cellular sources of TF within the vascular compartment are diverse and TF prothrombotic activity is typically controlled by cellular activation, including for TF expressed by smooth muscle cells [12, 13] . Although TF expression by platelets has been discussed controversially, generation of platelet-like particles from in vitro differentiated human megakaryocytes demonstrates that platelets can carry both TF protein and mRNA in distinct subpopulations [14] and platelet activation can induce splicing of intronretained TF mRNA for TF protein translation [15] .
In mouse endothelial cells, increased reactive oxygen species (ROS) production following deficiency of the antioxidative protein paraoxonase-2 (PON2) causes an upregulation of TF activity. Coagulation abnormalities in Pon2-deficient mice are indicated by shortened clotting times in vitro, likely reflecting pre-activated coagulation factors, and are reversed by restoration of PON2 expression in endothelial cells [16] . Deficiency of sirtuin 3 (Sirt3), another anti-oxidative molecule inactivating superoxide dismutase 2 (SOD2), increases myeloid cell TF prothrombotic function in experimental murine thrombosis in vivo in the context of inflammation induced by endotoxin [17] . The previously underappreciated expression of TF by endothelial cells plays a major role in sickle cell disease (SCD) pathology. In this context, myeloid cell TF is responsible for coagulation activation in mouse models of SCD, but endothelial cell TF primarily contributes to PAR2 signaling-dependent vascular inflammation [18] .
Genetic evidence supports the crucial role for myeloid cell-expressed TF in thrombosis [19, 20] , but TF synthesized by monocytes or neutrophils probably contributes to distinct pathologies. In the localized laser-induced vessel injury in mice, endothelial cells release adenosine triphosphate (ATP) that triggers P2X1 receptors on neutrophils being recruited, through interaction of lymphocyte function-associated antigen 1 (LFA-1) with intercellular adhesion molecule 1 (ICAM-1), to the injury site [21, 22] . TF is expressed by neutrophils and triggers thrombin and fibrin generation, as well as subsequent platelet recruitment and thrombus formation. Activation of neutrophils is required for TF exposure on the cell surface and neutrophil elastase enhances prothrombotic TF activity by degrading TFPI [23] . In this and other TFdependent arterial thrombosis models [24] [25] [26] , contact pathway FXII activation of FXI significantly contributes to thrombus stability and vascular occlusion.
Mouse neutrophil activation and the formation of neutrophil extracellular traps (NETs) contribute to thrombus stability [27] , but initial TF-dependent fibrin formation in flow-restricted venous thrombosis is normal in NETosisdeficient mice [20] . In patients with sepsis, autophagy delivers TF to NETs released during activation, leading to exposure of prothrombotic TF [28] . Human neutrophils are also primed in atherosclerotic vessels to upregulate TF that can be subsequently exposed by neutrophils interacting with thrombin-stimulated platelets [29] .
Eosinophils are among the neutrophil populations detected in thrombi from patients with in-stent thrombosis [30] and epidemiological studies link the eosinophil activation marker, eosinophil cationic protein, to thrombotic events [31] . Human eosinophils carry TF in intracellular granules and stimulation with platelet-activating factor (PAF) or granulocyte macrophage colony-stimulating factor causes TF translocation to the membrane, where it can initiate coagulation and supports transendothelial migration [32] . Coagulation activation by eosinophils not only requires TF, but also the enzymatic modification of procoagulant phospholipid. Eosinophil activation induces surface exposure of 12/15-lipoxygenase-modified hydroxyeicosatetraenoic acid (HETE) phosphatidylethanolamines necessary for procoagulant activity, thrombin generation and thrombosis [31] . Phosphatidyl ethanolamine (PE) is modified by the 12/15 lipoxygenase Alox15 expressed by eosinophils and Alox15 knock-out mice display reduced thrombosis. This and other studies provide evidence that immune cell-derived enzymatically oxidized HETE phospholipids play broader roles in prothrombotic and hemostatic reactions [33] .
Myeloid cell TF activation in the context of inflammation
Whereas neutrophils typically translocate TF to the cell surface or to generated NETs, monocytes and macrophages express TF on the surface in an inactive or cryptic form that is converted to fully procoagulant TF by specific inflammatory agonist pathways. TF activation on monocytes or macrophages requires thiol-disulfide exchange and involves protein disulfide isomerase (PDI). Although PDI can be acutely released during vessel wall injury [34] , in vitro studies demonstrate that PDI is detectable on the surface of intact cells [35] in complex with TF [36] and PDI on extracellular vesicles (EV) directly regulates TF activity [12] .
The precise post-translational modifications of cryptic TF may differ between vascular and extravascular cells, but the TF extracellular allosteric disulfide bond Cys 186 -Cys 209 can be S-nitrosylated, reduced or converted to mixed disulfides of TF Cys 209 with thioredoxin (Trx) or glutathione [37] . When the allosteric disulfide is oxidized, affinity for FVIIa is high and recognition of macromolecular substrate FX is favored [36] . However, exposure of procoagulant phospholipid in the context of cellular activation is required, albeit insufficient alone, for the TF activity switch that involves thiol-disulfide exchange and PDI ( Fig. 2A) . Moreover, agonists that activate TF frequently cause the release of EV with prothrombotic activities and thus couple local inflammatory reactions to remote propagation of thrombosis.
Protein disulfide isomerase has multiple targets during thrombus formation in vivo [38] , but it plays a direct role in the function of prothrombotic EV released from myelo-monocytic and vessel wall cells activated by P2rX7 stimulation with the cell injury signal ATP [25] . ATP activation of P2rX7 is the central mechanism for cellular processing and release of interleukin (IL) 1b, which participates in a variety of inflammatory and cardiovascular diseases. In endotoxin-primed mouse macrophages, this pathway triggers endosomal ROS production required for Trx reductase-dependent inflammasome and caspase-1 activation [13] . Release of Trx from intracellular targets, including the inflammasome activator Trxinteracting protein (TXNIP), permits cytoskeletal changes and filopodia formation (Fig. 2B ). Reduced Trx is released into the extravascular space and responsible for reductive changes in cell surface proteins and required for TF incorporation into EV. Most important, inflammasome-generated caspase-1 promotes actin translocation across membranes and thereby enables the final severing of thrombo-inflammatory EV with a unique protein composition forming on filopodia.
Inhibition of glycosphingolipid-rich raft domains with the cholesterol chelator filipin prevents TF trafficking to filopodia and release onto EV [13] . In vitro, the major raft component sphingomyelin markedly suppresses TF activity in the presence of procoagulant phosphatidylserine (PS) [39] , providing a supportive mechanism for TF encryption prior to cell activation. ATP stimulation rapidly increases PS levels on the outer membrane independent of Trx reductase [13] , but TF activation requires the degradation of sphingomyelin by acidic sphingomyelinase, which is activated independent of PDI [39] . Although PS is detectable after activation on macrophages and derived EV, the procoagulant activity of EV is most efficiently inhibited by duramycin, an antagonist of PE, and less so by lactadherin, which specifically blocks PS [12] . PE is emerging as an important lipid in thrombosis because it also supports the prothrombotic activity of cancer cell-derived EV [40] . A challenge for future translational coagulation research will be the development of assay systems incorporating such lipid components, which in cell-based and preclinical models emerged as relevant coagulation amplifiers.
The exposure of procoagulant phospholipids is essential for conversion of TF from a cryptic to a prothrombotic form. A molecular dynamic simulation of TF-FVIIa on a lipid surface revealed direct interactions between TF extracellular domain residues and the negatively charged headgroup of PS [41] . These TF residues are important for macromolecular substrate turnover [42] , suggesting a mechanism by which TF structural changes in the carboxyl terminus are influenced by a procoagulant lipid environment. However, PS exposure is typically not sufficient for TF activation on cells and requires additional thiol-disulfide exchange-mediated alterations in the TF protein.
As one example, macrophage TF surface availability is regulated by integrin a4b1 controlling the activity of ADP-ribosylation factor 6 (arf6), which is involved in integrin recycling [12] . Blockade of dynamin-dependent integrin internalization exposes PS and generates EV with TF and PS levels as seen following ATP stimulation; however, these EV lack PDI and have low prothrombotic activity in flowing blood [12] . A distinction between these two types of EV is the affinity of TF for its ligand FVIIa. The PDI chaperone function enhances TF-FVIIa affinity and is blocked by an antibody to TF, 10H10 [43] , which reduces EV TF-FVIIa affinity and markedly diminishes EV prothrombotic activity [12] . Similarly, monocyte TF is activated by antiphospholipid antibodies (aPLs) that expose PS independent of PDI, but TF activation nevertheless requires the PDI oxidoreductase function and TF interactions that are blocked by anti-TF 10H10 [43] .
Reduction of the TF allosteric disulfide by Trx is one elucidated mechanism that suppresses TF activity on monocytes. Inhibition of Trx is sufficient to increase TF activity in the context of PS exposure [44] . In addition, the complement cascade has emerged as an important activator of encrypted TF on monocytes in vivo. The polyclonal anti-thymocyte globulin (ATG) preparation is used for prevention and treatment of allograft rejection and graft-versus-host disease, but some patients develop low-grade intravascular coagulation during therapy. ATG rapidly induces procoagulant activity of preformed TF on the surface of monocytic cells, dependent on Fc-mediated complement activation in vitro [35] . TF conversion to an active form in this context requires PDI and thiol-disulfide exchange, which is known to occur during complement activation (Fig. 2A) . Formation of the membrane insertion complex C5b-7, but not the full assembly of the C5b-9 terminal complement complex, is sufficient for PS exposure supporting TF activation.
In addition, TF on human and mouse monocytes is activated by complement-fixing aPLs. Whereas PDI and C3 are involved, as seen with ATG, the exposure of PS and TF activation are independent of C5 ( Fig. 2A) . These aPLs, which are not reactive with the b2-glycoprotein I cofactor, induce thrombosis independent of C5 and lowdensity lipoprotein receptor-related protein 8 (Lrp8) interacting with b2-glycoprotein I. In contrast, C3 deficiency prevents amplified venous thrombus formation in an inferior vena cava thrombosis model in mice, consistent with the in vitro properties of aPLs in TF activation [43] . Complement activation is also crucial in flow-restricted venous thrombosis models in the mouse. Imaging of platelet and fibrin deposition has revealed distinct roles for C3 and C5 in this context [20] . Platelet activation is reduced in C3-deficient mice, but no defect is seen in C5-deficient mice, indicating direct activation of platelets by C3 products independent of terminal complement. On the contrary, in this model of myeloid cell TF-dependent thrombosis, PDI inhibitors as well as C3 and C5 deficiency attenuate fibrin deposition. In addition, C5-deficient mice display reduced PS exposure on leukocytes that are recruited efficiently to the flow-restricted vessel wall. Thus, complement-coagulation crosstalk plays an important role in pathologies driven by monocyte TF expression.
TF-FVIIa and intracellular signaling
Apart from controlling coagulation, cellular mechanisms that render TF non-coagulant also support TF-FVIIa cell signaling. Coagulation proteases, including TFFVIIa, TF-FVIIa-FXa, thrombin and activated protein C (aPC), cleave the extracellular domains of PARs and elicit both heterotrimeric G protein and b-arrestincoupled signaling [45] . Although all coagulation proteases can cleave PARs with variable efficiency, protease interactions with specific receptors, their subcellular localization in microdomains, PAR heterodimerization and alternative PAR cleavages result in biased agonism and sometimes opposing downstream cellular responses. Understanding the precise signaling pathways elicited by the coagulation proteases is important for predicting potential therapeutic benefits of, for example, biased antagonists for PAR2 [46] .
TF plays a central role in PAR signaling and forms two distinct signaling complexes (Fig. 3) . In the TFFVIIa-Xa-endothelial protein C receptor (EPCR) complex, TF-FVIIa-generated nascent product FXa cleaves PAR1 or PAR2 [47] . This signaling occurs at low concentrations of FVIIa (< 1 nM) and the TF molecule requires the presence of the Cys 186 -Cys 209 disulfide bond to have high affinity for FVIIa, full coagulant activity, and ternary TF-VIIa-Xa complex signaling [36] . In contrast, the binary TF-FVIIa complex cleaving PAR2 is formed by TF with low affinity for binding FVIIa, requiring high FVIIa concentrations (1-20 nM) (Fig. 3A) . Reduction of the TF Cys 186 -Cys 209 allosteric disulfide bond decreases affinity for FVIIa without completely abolishing ligand binding, while fully preserving cell signaling when Cys 186 is present, indicating a cell signaling role for this residue, potentially through mixed disulfide formation [36] .
Although aPC bound to EPCR is the prototypical PAR1 activator [48] and the FVIIa light chain cannot substitute for the same region in aPC in signaling [49] , FVIIa in complex with EPCR also elicits TF-independent PAR1 signaling in endothelial cells [50] . In contrast, the binary TF-FVIIa complex activates PAR2 and has been linked to a variety of pathological conditions. In many cases, pathological TF-FVIIa signaling involves the short cytoplasmic domain of TF that in human TF is phosphorylated at Ser 253 by protein kinase C (PKC) [51, 52] and at Ser 258 by mitogen-activated protein (MAP) kinase p38 [53] , resulting in conformational changes influencing ligand binding [54, 55] . PAR2 cleavage and certain proximal signaling responses of TF-FVIIa do not require the TF cytoplasmic domain [56] . Instead, the TF cytoplasmic domain recruits adaptors for signaling complexes and protein trafficking (i.e. the regulatory subunit of phosphatidylinositol 3 kinase [PI3K]) [57] , the actin binding protein filamin [13, [58] [59] [60] and the prolyl-isomerase Pin1 [55, 61] . Interaction of the TF cytoplasmic domain with Pin1 not only influences TF protein half-life and incorporation into EV, but also Pin1-dependent transcriptional regulation of TF expression in human smooth muscle cells [55] . It is currently unclear whether Pin1 regulation involves PAR2, which is known to constitutively signal independent of proteolytic cleavage [62] . In contrast, binding of the regulatory subunit of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) to the TF cytoplasmic domain is important for TF-FVIIa-PAR2 signaling that is connected to functions of cell adhesion receptors, particularly integrins of the b3 and b1 families [57] .TF-FVIIa complex signaling through PAR2 has been implicated in cancer cell migration, invasion, proliferation and evasion from apoptotic cell death [56] , Blocking the TF-integrin interaction with anti-TF antibody 10H10, which has minimal effects on coagulation, inhibits TF-FVIIa signaling and suppresses tumor growth [63] . Other TF-FVIIa inhibitors also prevent spontaneous tumor progression in syngeneic tumor models [64] . The interaction of TF with integrins is complex. Alternative splicing of TF creates a soluble isoform of TF without a transmembrane and cytoplasmic domain [65] . Although alternatively spliced TF (asTF) does not support physiological roles of TF (e.g. in embryonic development [66] ), it retains the ability to ligate integrins avb3 and a6b1 [67] , which also interact with full-length TF [68] . Signaling of asTF is independent of FVIIa-PAR2 and promotes, through direct integrin ligation of endothelial cells, angiogenesis [67] and inflammation [69] , or cancer cell survival [70] .
The molecular details of TF-FVIIa complex formation with integrin and implications for proangiogenic and promigratory signaling have recently been further clarified. Immunoprecipitation with an antibody recognizing an active conformation of b1 integrin has shown that FVIIa induces TF complex formation with activated integrin through a specific binding site in the FVIIa protease domain remote from the catalytic cleft required for PAR2 cleavage [57] . This site overlaps with the macromolecular substrate binding site [1] and thereby precludes the activation of procoagulant substrates with a predicted impairment of TF-initiated coagulation. Signaling of the integrin-TF-FVIIa complex may therefore occur without interference from downstream thrombin signaling events.
TF-FVIIa-PAR2 signaling involves endosomal internalization of TF-FVIIa together with activated integrin dependent on the small GTPase arf6 (ADP-ribosylation factor 6), a regulator of integrin trafficking. Complex formation of TF-FVIIa with integrin is not required for PAR2 cleavage, but drives delayed mitogen-activated kinase signaling and PI3 kinase activation required for the expression of proangiogenic cytokines [57] . FVIIa catalytic activity and the TF cytoplasmic domain are dispensable for formation of the TF-FVIIa-integrin complex but required for PI3K-dependent IL8 induction and cell migration [57, 68] . PI3K plays a crucial role in TFFVIIa enhanced cancer cell migration through its downstream target protein kinase B (PKB, Akt). TF-FVIIa-PAR2-mediated Akt phosphorylation and inactivation of glycogen synthase kinase-3b (GSK-3b) result in b-catenin stabilization and gene transcriptional activation of promigratory and prometastatic genes [71] . In addition to integrins, TF-FVIIa proangiogenic signaling in non-cancerous keratinocytes depends on transactivation of epidermal growth factor receptor (EGFR) and proline-rich tyrosine kinase 2 (PYK2) [72] . The TFFVIIa complex also mediates transactivation of the insulin growth factor receptor (IGF-1R), preventing TRAIL (TNF-related apoptosis inducing ligand) dependent apoptosis in cancer cells [73] . The binary TF-FVIIa complex, but not the ternary TF-FVIIa-FXa or downstream coagulation proteases, induces cleavage of the ectodomains of tyrosine kinase receptors EphB2 and EphA2, which increases cell motility [74] . PAR2 signaling and, based on antibody blockade, TF-FVIIa-integrin interaction are not required for cleavage of a conserved arginine residue in the ligand-binding domain of Eph receptors. Extracellular cleavage of ephrins apparently does not involve downstream matrix metalloproteinases and is dependent primarily on serine protease activity. Additionally, TF-FVIIa has recently been shown to activate the transmembrane serine protease matriptase [75] . Although TF-FVIIa-PAR2 proangiogenic signaling is independent of matriptase [57] , the role of matriptase in PAR2-independent TF-FVIIa-triggered cell surface proteolysis requires further study. FVIIa mutant proteins defective in integrin complex formation and PAR2 cleavage will be useful tools to better understand the divergent roles of TF-FVIIa cell signaling pathways in vitro and in vivo [57, 76] .
TF-PAR2 signaling in inflammatory diseases and cancer
Mice with a deletion of the TF cytoplasmic domain (TF DCT mice) have helped to identify roles of TF-PAR2 signaling in physiology and pathology. TF DCT mice display increased developmental and hypoxia-driven angiogenesis that is reversed by PAR2 deficiency or inhibitors of TF-FVIIa [77, 78] . Although these and other studies [79, 80] indicate a regulatory role for the TF cytoplasmic domain, TF DCT mice and PAR2 À/À display similar pathology-protected phenotypes in other models [81] . Spontaneous breast cancer development is delayed in both strains and to a similar extent in double-deficient mice, indicating that PAR2 and downstream TF cytoplasmic domain phosphorylation cooperate in cancer progression, consistent with human pathology data in breast cancer [82] . TF-FVIIa-PAR2 signaling has also been linked to human hepatocellular carcinoma (HCC) progression independent of downstream coagulation [83] . In addition, TF DCT and PAR2-deficient mice were similarly protected from carbon tetrachloride (CCl 4 ) damage leading to hepatic fibrosis involving transforming growth factor (TGF) b and macrophage activation. The TF cytoplasmic domain regulates TF trafficking in intestinal epithelial cells and gut microbiota promote Nglycosylation of TF and TF surface localization in enterocytes. The TF cytoplasmic domain and PAR1 signaling are both required for adaptive angiogenesis following colonization of the small intestine with microbiota [84] . Although thrombin-PAR1 signaling triggered TF phosphorylation in enterocytes, it will be of interest for future studies to define which endogenous or microbiota-derived proteases can contribute to the regulation of intestinal homeostasis via PAR signaling.
Obesity is characterized by a hypercoagulable state and associated with increased risk of thrombosis [85] . In adipocytes, the TF cytoplasmic domain participates in TFFVIIa-induced suppression of Akt phosphorylation by insulin and thus impairs expression of negative regulators of weight gain. Accordingly, blocking TF-FVIIa interaction with an antibody in obese mice improves overall metabolism and energy expenditure [86] . TF is upregulated in the obese visceral adipose tissue and fibrin deposition is prominent, surrounding the 'crown-like' structure where macrophages interact with stressed adipocytes. In mouse models, a genetically induced hyper-thrombotic state promotes obesity, but a mutant of fibrinogen devoid of interaction with the macrophage-expressed integrin aMb2 (CD11b/CD18) is protected from diet-induced obesity with diminished systemic and adipose inflammation [87] .
In addition, TF is expressed by adipose tissue macrophages and loss of TF-PAR2 signaling in hematopoietic cells prevents the development of adipose tissue inflammation and insulin resistance, key contributors to the development of type 2 diabetes and the metabolic syndrome [86] . In the liver, TF-PAR2 signaling drives the accumulation of CD8 + T cells and promotes pathways of hepatic lipogenesis and gluconeogenesis that contribute to steatosis and hepatic insulin resistance [88] . Hepatic inflammation is also reduced in mice treated with the thrombin inhibitor dabigatran or defective macrophage fibrin interaction [87] . Thus, coagulation-induced fibrin deposition participates in inflammatory TF-PAR2 signaling in prevalent diseases of metabolic inflammation.
PAR2 signaling of TF-FVIIa-generated nascent product FXa As discussed above, initial studies showed that low concentrations of FVIIa elicit cell signaling only when FX was present [89] and that FXa associated with the TFFVIIa complex efficiently cleaves PAR2 [90] . Because procoagulant and prothrombotic TF binds FVIIa with high affinity [12, 36] , signaling of the nascent product FXa is integrated in cell surface TF-initiated coagulation (Fig. 3B) . This pathway may proceed without significant thrombin generation and thrombin-dependent PAR signaling, because TFPI controls the generation of active prothrombinase, as discussed above. In addition, TFFVIIa-Xa ternary complex signaling is directly regulated by TFPI, which suppresses PAR responses [91] and promotes lipid raft-dependent recycling of the inhibited TF complex [92] . TF ternary complex signaling in endothelial, smooth muscle and cancer cells also requires EPCR, but not Gla-domain interactions of FVIIa with EPCR [47] .
Although EPCR mediates endothelial protection in endotoxemia inflammation models [93] , EPCR is crucial for signaling of the TF-FVIIa-FXa complex and the lipopolysaccharide (LPS) mediated activation of dendritic cells [94] . Whereas PAR2 and toll-like receptor (TLR) 4 form a heterodimer and PAR2 in general synergizes with TLR innate immune signaling [95, 96] , the TF-FVIIaFXa-EPCR complex selectively induces expression of the TLR3/4 signaling adaptor protein pellino-1, the transcription factor interferon (IFN) regulatory factor 8 (IRF8) and a set of IFN-regulated genes. This signaling response is absent in EPCR-, PAR2-and TF-deficient cells following endotoxin stimulation in vitro and in vivo [94] . The induction of these genes downstream of TLR4 activation is blocked by anti-TF antibody inhibiting FVIIa binding or FXa inhibitors. Remarkably, stimulation with a direct PAR2 agonist restores the induction of this gene pattern when FXa is blocked, but not when the assembly of the TF-FVIIa complex is inhibited by anti-TF antibody. Thus, TF-FVIIa generation of FXa activating PAR2 and the formation of the TF-FVIIa-FXa-EPCR complex are an integral part of the TLR4 innate immune responses.
The cooperative role of TF initiation complex signaling in innate immune cells is regulated by the anticoagulant PC pathway (Fig. 3B) . Thrombin-thrombomodulin activation of PC limits coagulation activation by inactivating the plasma coagulation cofactors FVa and FVIIIa. In addition, non-activated FV is a cofactor for aPC degradation of FVIIIa and this reaction requires the anticoagulant protein S. This pathway is defective in homozygous FV Leiden patients, but functional or even amplified in inflammatory conditions due to increased thrombin generation in heterozygous FV Leiden carriers. The aPC-PS-FV, but not FVa or FV Leiden , triad turned out to be a potent suppressor of inflammatory PAR2 signaling induced by the TF-VIIa-Xa-EPCR complex [97] , identifying a novel regulation of the TF pathway signaling by the downstream anticoagulant pathway. Additional experiments showed that stabilizing the TF-FVIIa-FXa complex with a unique inhibitor or disabling aPC binding to EPCR prevents the regulation of the TF-dependent IFN response downstream of TLR4, indicating a mechanism of competition between aPC and FXa for recruiting EPCR to distinct signaling pathways. The regulation of TF signaling by aPC is also relevant for sepsis therapy. Treatment of septic mice with a signaling selective aPC variant with greatly diminished anticoagulant function reduces mortality; this beneficial effect is lost in homozygous FV Leiden mice. These experiments emphasize that both pro-and anticoagulant pathways are integrated into innate immune responses to microbial threats and potentially a variety of other endogenous danger signals.
TF-dependent signaling in endothelial cells
Endothelial cell-expressed TF also participates in inflammation, predominantly through cell signaling rather than coagulation activation. Although endothelial cell expression of TF has long been considered of little importance for pathological processes, the inflamed pulmonary vein endothelium in SCD expresses TF dependent on direct effects of hemolysis and leukocyte crosstalk [18] . The TF pathway is crucial for both coagulation abnormalities and chronic vascular inflammation in SCD, but endothelial cell-specific deletion of TF in a mouse model of SCD prevents selectively the upregulation of IL6, without changing markers of intravascular coagulation [18] . Blocking TF and anticoagulation with the thrombin inhibitor dabigatran or the FXa inhibitor rivaroxaban effectively reduces lung leukocyte infiltration. However, only FXa inhibition reduces IL6 levels, as also seen in anti-TF-treated or PAR2 knock-out mice. Although the participation of other components of the TF complex has not been analyzed, these data indicate a non-coagulant role for endothelial cell-expressed TF in vascular inflammation.
As mentioned above, endothelial cell TF is regulated by the anti-oxidative protein PON2, a cell-associated protein with anti-atherogenic properties. Pon2 deficiency causes a post-transcriptional upregulation of endothelial cell TF activity and a proinflammatory state that is reversed by genetic restoration of PON2 in endothelial cells, antioxidant treatment and antibody inhibition of TF [16] . Similar to SCD mice [18] , Pon2 deficiency increases endothelial cell IL6 expression and CCL22 that is also regulated by ternary complex signaling in myeloid cells [94] . Loss of PON2 antioxidant function causes vascular inflammation and dysfunction that is reversed by anti-TF treatment. Knock-down of FVII synthesis in the liver and reduced circulating FVII levels increase hemorrhaging following cerebral contusion injury in mice [98] . Infusion of recombinant FVIIa restores microvascular function, prevents endothelial cell apoptosis and protects the brain. In vitro experiments with endothelial cells induced with inflammatory mediators to express TF show that TF-FVIIa-FXa complex signaling through PAR2 suppresses p65 NF-jB phosphorylation independent of EPCR but increases MAP kinase signaling dependent on EPCR. Although TF-FVIIa-FXa, through downstream activation of matriptase and PAR2, is barrier-protective in epithelial cells [75] , in vivo experiments are necessary to better understand the effect of plasma FVII levels on endothelial protection in the brain. FVIIa is barrier-protective through TF-independent but EPCR-dependent PAR1 signaling [99] , indicating overlapping functions of FVIIa with the endothelial protective aPC pathway. Mutant mouse models that are resistant to certain coagulation proteases [76, 94, 100] will be useful tools for future studies on the distinct roles of coagulation factors in vascular biology.
Conclusions and outlook
These studies have revealed new details of TF interactions contributing to the diverse TF functions in hemostasis, thrombosis and inflammation. TF is linked in its cellular regulation to intracellular adaptors and integrin trafficking pathways and thereby contributes to physiological control of cells. Inflammatory activation of cells can divert TF from these trafficking routes and cause pathologies, as illustrated for the generation of thromboinflammatory EV. Understanding these cellular and PAR signaling routes of TF will be essential for predicting effects of targeted selective anticoagulants and devising new approaches that selectively interfere with pathological TF functions without perturbing hemostatic or protective signaling. This knowledge should be translated into the improved diagnostic approaches required for the ultimate goal of individualized therapies in TF-dependent pathologies.
